Artivion, Inc. (NYSE:AORT) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $42.86.

Several brokerages recently commented on AORT. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Canaccord Genuity Group lifted their price target on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Jefferies Financial Group started coverage on shares of Artivion in a report on Tuesday. They issued a “buy” rating and a $31.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Finally, Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th.

Artivion Trading Up 3.8%

Artivion stock opened at $23.12 on Wednesday. The business has a 50 day moving average price of $24.69 and a two-hundred day moving average price of $26.10. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of 41.26 and a beta of 1.23. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, equities analysts forecast that Artivion will post 0.45 EPS for the current year.

Insider Activity

In related news, CEO James Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jean Holloway sold 977 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the transaction, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This trade represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares during the period. Versant Capital Management Inc boosted its stake in shares of Artivion by 38.0% in the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock valued at $48,000 after purchasing an additional 584 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Artivion in the 2nd quarter valued at $103,000. Pictet Asset Management Holding SA grew its holdings in shares of Artivion by 25.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 5,520 shares of the company’s stock worth $202,000 after purchasing an additional 1,125 shares during the last quarter. Finally, R Squared Ltd grew its holdings in shares of Artivion by 29.5% in the 1st quarter. R Squared Ltd now owns 6,051 shares of the company’s stock worth $222,000 after purchasing an additional 1,379 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device company focused on products and services for cardiac and vascular surgery. The company develops, manufactures and distributes implantable devices, surgical adhesives and preserved human tissues used in the treatment of complex cardiovascular conditions.

Its product portfolio includes On-X mechanical heart valves and related repair technologies, BioGlue surgical adhesive, aortic stent grafts and other devices for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in surgical procedures.

The company was formerly known as CryoLife, Inc and adopted the Artivion name in 2021 to reflect its broader focus on cardiovascular and aortic therapies.